Publication | Closed Access
The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors
271
Citations
19
References
2002
Year
Immune ToleranceImmunologyPharmacotherapyOutcome PredictorsVaccine HesitancyImmunotherapyClinical EpidemiologyHematologyOral ImmunotherapyPublic HealthPrimary ImmunodeficiencyAutoimmune DiseaseAllergyAccess CathetersSelf-toleranceHumoral ImmunityAutoimmunityNephrotic SyndromeTolerance InductionEpidemiologyVaccinationVaccine EfficacyImmunosuppressionMedicine
The findings are contextualized within the international ITT registry and an upcoming prospective ITT study. The North American Immune Tolerance Registry was initiated to study immune tolerance in Canada and the United States, focusing on therapeutic regimens for haemophilia A and B inhibitor patients, therapeutic outcomes, potential predictors of success, and therapy complications. Data on 188 ITT courses were collected by questionnaire from 60 haemophilia centers between 1993 and 1999. Among 164 completed courses, ITT success was 70 % for haemophilia A and 31 % for haemophilia B; in haemophilia A, higher pre‑ITT induction, peak, and historical peak inhibitor titres predicted success, while higher total daily dose was inversely associated with success, and failures were more likely to experience adverse reactions and catheter infections, though outcome predictors were not evaluable for haemophilia B.
The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitor titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with > or = 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.
| Year | Citations | |
|---|---|---|
Page 1
Page 1